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Ferenc Fülöp*[a,d]
Abstract: The synthesis of racemic and enantiopure tricyclic
and tetracyclic pyrrolopyrimidinones, pyrimidoisoindoles, and
spiropyrimidinones, as valuable new chemical entities (NCE),
based on a highly controlled continuous-flow (CF) retro-Diels–
Alder protocol is presented. This approach ensures enhanced
safety, and gave the target pyrimidinone derivatives 17–25 in
yields higher than those obtained in batch and microwave
Introduction
Heterocyclic skeletal transformations are some of the most
powerful synthetic methods for the construction of complex
molecular frameworks from simple feedstocks.[1] In this context,
Diels–Alder (DA) and retro-Diels–Alder (rDA) reactions are the
prevailing approaches, since they lead to valuable N-hetero-
cycles with high biological activities, such as isoindoloquinaz-
olinones, pyrroloquinazolinones, and 2-spiroquinazolinones.
The reactivity and skeletal transformations of these compounds
under mild conditions have been widely examined and dis-
cussed by our group.[2] The DA/rDA approach makes use of
the rigidity and chirality of the DA adducts that are formed by
reactions between cyclic dienes and cyclic dienophiles.[3,4] The
rDA enantiomers are obtained when enantiomerically pure DA
products are modified diastereoselectively and then undergo
thermal [4+2] cycloreversion through distillation under reduced
pressure[5] or boiling in a solvent,[6] or through the use of micro-
wave (MW) irradiation[7] or flash vacuum pyrolysis.[8]
We recently revealed the potential of the use of continuous-
flow (CF) technology for the synthesis of various functionalized
pyrimidinone systems through rDA reactions.[9] Our interest in
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processes. These results were achieved through careful optimi-
zation of the reaction parameters. We also developed an alter-
native time-efficient route for the synthesis of intermediate
quinazolinones 2–16 involving a three-step domino ring-clo-
sure reaction followed by spirocyclization under continuous-
flow conditions, starting from -aminonorbornene carbox-
amides 1a–1d and γ-keto acids or cycloalkanones.
CF processes can be explained, at least in part, by the number
of potential advantages that CF processes have over traditional
batch chemistry. These include the ease of scale-up, high repro-
ducibility, excellent heat transfer and mixing, as well as the in-
herently greater safety resulting from the small reactor vol-
umes.[10–19] Moreover, the accurate tuning of residence times
can further broaden the versatility of CF processes.[20] Thus,
flow chemistry has for a long time been chosen as an efficient
method for the synthesis of more complex chemical structures
that are otherwise inaccessible.
Focussing on the biological potential of fused pyrimidinones,
and continuing our work on the synthesis of new N-hetero-
cycles, we intended to further capitalize on the CF rDA protocol
by synthesizing more complex pyrimidinone-fused moieties in
both racemic and enantiopure forms. Pyrrolopyrimidines have
a wide range of applications in medicinal chemistry; they show
antimicrobial,[21] antitumor,[22] antiasthmatic,[23] antihyperten-
sive,[24] and anti-inflammatory[25] activities. Pyrimidoisoindoles
show high vasorelaxtant,[26a] antiplasmodial,[26b] and antifun-
gal[27] actions. The spiroquinazolinone, spiropiperidine, and
spiroadamantane skeletons, in turn, are known to have a wide
range of pharmacological properties, including antimalarial[28]
and anti-influenza activities.[29] Moreover, they also function as
inhibitors of several key enzymes, such as nitric oxide syn-
thase[30] and nosine-5′-monophosphate dehydrogenase.[31] In
addition, they are present in several natural frameworks, e.g.,
prostanoids, alkaloids, and nucleosides.
In this paper, we describe an extension of our previously
reported CF rDA process for the synthesis of racemic and
enantiopure tricyclic and tetracyclic pyrrolopyrimidinones, pyr-
imidoisoindoles, and spiropyrimidinone derivatives. We have
also developed an alternative preparation for quinazolinone in-
termediates by: (i) a three-step domino ring-closure reaction,
and (ii) spirocyclization under CF conditions with diexo- and
diendo--aminonorbornene carboxamides and γ-keto acids or
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cycloalkanones as starting materials. The developed flow-based
method gave the desired pyrimidinones in high yields, and en-
sures enhanced safety.
Results and Discussion
Our previous investigations on the CF rDA reactions of con-
densed pyrimidinone derivatives revealed that the CF approach
is superior to existing conventional batch methods.[9] In this
work, starting materials were selected with the aim of testing
the viability of the proposed CF rDA protocol with more com-
plex fused pyrimidinone moieties, and also of investigating mo-
lecules that have never been subjected to rDA reactions under
batch conditions. We started our study with readily available
aminocarboxamides 1a–1d, which were prepared by known lit-
erature approaches. Both diendo- and diexo-3-aminobicy-
clo[2.2.l]hept-5-ene-2-carboxylic acids, as well as diexo-3-amino-
7-oxabicyclo[2.2.1]hept-5-enecarboxylic acid, were esterified
with ethanol, and the resulting ester bases were liberated from
the hydrochlorides. These aminoesters were kept for three
weeks in a large excess of methanol saturated with ammonia
to give amides 1a, 1c, and 1d.[2d,2f,2l] For the preparation of 3-
exo-amino-N-methylbicyclo[2.2.l]hept-5-ene-2-exo-carboxamide
(1b), a mixture of the appropriate ester and a methylaminesolu-
tion (25 % in methanol) was kept for 6 d at room tempera-
ture.[2e] Our synthetic efforts began with the preparation of the
required intermediates 2–16 using an optimized procedure
based on previously reported methods,[2l–2r] as illustrated in
Schemes 1 and 2.
Scheme 1. Solvent and conditions: (i) toluene, reflux, pTsA, 16 h;[2l–2n] (ii) CF: toluene, flow rate = 0.2 mL min–1, 110 °C, pTsA, 6 h.
Scheme 2. Solvent and conditions: (i) 8, 9: solventless, room temp., 2 d.[2q] 10: EtOH, reflux, 2 h.[2o] 11–13: H2O, room temp., 24 h;[2q] (ii) CF: EtOH, flow rate =
0.2 mL min–1, 100 °C, 6 h; (iii) MW: EtOH, 100 °C, 1 h; (iv) CF: EtOH, flow rate = 0.2 mL min–1, 100 °C, 6 h.
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The cyclization reactions of racemic diexo-3-aminobicyclo-
[2.2.1]hept-5-ene-2-carboxamide (1a) or diexo-3-N-methylbicy-
clo[2.2.1]hept-5-ene-2-carboxamide (1b) with γ-oxocarboxylic
acids in toluene under reflux in the presence of para-toluene-
sulfonic acid (pTsA), through three-step domino reactions, re-
sulted in single diasteroisomers of pyrrolo[1,2-a]quinazolines 2–
4 or isoindolo[2,1-a]quinazolines 5–7 (Scheme 1). Upon heating
with cyclohexanone in refluxing ethanol (EtOH), -aminonor-
bornene carboxamides 1a, 1c, and 1d were cyclized to give
methylene- and epoxy-bridged 2-spiroquinazolinones 8–10.
These compounds could alternatively be prepared under dry
(solvent-free) conditions by stirring for 2 d; spiropiperidine de-
rivatives 11–13 were formed by the condensation of carbox-
amides 1a, 1c, and 1d with 1-benzylpiperidin-4-one in water at
room temperature (Scheme 2).
For the preparation of spiro[quinazoline-2,2′-adamantane]
derivatives 14–16, we developed an alternative synthetic path-
way involving the use of MW irradiation on 1a, 1c, 1d with
adamantanone in EtOH (Scheme 2). This reaction has previously
also been carried out in a vibrational ball mill with iodine (I2)
as a catalyst.[2r] In additition, we wanted to further develop this
cyclization method by searching for a time-efficient method for
the synthesis of functionalized intermediates 2–16. To this end,
a CF-based strategy seemed highly appropriate , since this ap-
proach has emerged as an intense area of current research, be-
ing used for the synthesis of many different heterocyclic scaf-
folds.[32] -Amino amides 1a–1d were mixed with γ-keto acids
or cyclic ketones and loaded into the CF reactor constructed
previously (Figure 1), using the same operating conditions and
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solvents used before in batch syntheses. Mixtures of 1a or 1b
and γ-keto acids were dissolved in toluene, and introduced into
the flow reactor at 110 °C, with 6 h as the reaction time: Tetra-
and pentacyclic derivatives 2–7 were obtained in slightly higher
yields (79–93 %) than the previous batch method.Heating solu-
tions of 1a, 1c, or 1d with cycloalkanones in EtOH at 100 °C
gave spiroquinazolinones 8–16 with reaction times of 6 h in
similar yields (79–95 %). Note, however, that shorter reaction
times were needed for cyclization in the CF reactions (see
Table S1 in the Supporting Information).
Figure 1. Set-up of the continuous-flow reactor.
The residence time and reaction temperature are crucial de-
termining factors in flow chemistry;[20] they control the course
of a reaction by affecting both the conversion and the yield.
Thus, these two parameters were well-tuned for all starting ma-
terials. The residence time was set by the use of coils with differ-
ent lengths. The pressure and flow rate were kept at constant
values of 10 bar and 0.2 mL min–1, respectively. The reaction
process was monitored by means of HPLC–MS and 1H NMR
spectroscopic analysis.
Our next step was to investigate the transformation of quin-
azolinone derivatives 2–16 into retrodiene products 17–25
through a thermal [4+2] cycloreversion involving the elimina-
tion of cyclopentadiene or furan from DA adducts (Scheme 3).
We began by investigating the CF rDA reactions of tetra- and
pentacyclic derivatives 2–7, since these compounds include
Scheme 3. (i) CF: MeCN, toluene, flow rate = 0.2 mL min–1, 150–250 °C; (ii) heating at melting points; (iii) MW: 1,2-DCB (1,2-dichlorobenzene), 150–240 °C, 1 h.
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more complex fused pyrimidinone moieties, which might be a
challenge for our proposed CF rDA protocol.
We screened different solvents, and found that polar aprotic
solvents such as acetonitrile (MeCN) or methanol (MeOH) were
preferred over nonpolar solvents (dichloromethane, toluene),
especially when high concentrations were used. We thus opted
for MeCN as a suitable and benign solvent, and used it subse-
quently to study the effect of different temperatures. We
quickly established that temperatures of 220–250 °C gave full
conversions with a residence time of 15 min, without the un-
wanted thermal degradation of the rDA products; lower tem-
peratures slowed down the reactions significantly. Having es-
tablished these reaction conditions, tetracyclic pyrrolo[1,2-a]-
quinazolinones 2–4 and pentacyclic isoindolo[1,2-a]quinazolin-
ones 5–7 were dissolved in MeCN, and after 5 min of stirring
at ambient temperature, the homogeneous mixtures were in-
troduced into the reactor by an HPLC pump (Figure 1). Heating
the mixtures at 220 or 250 °C led to the expected pyrrolopyrim-
idinones 17–19 and pyrimidoisoindoles 20–22, with residence
times of 15 min (Table 1, entries 1–8) in isolated yields over
90 % after purification by column chromatography. These re-
sults match the parent batch experiments in terms of isolated
yields.[2l,2m]
To establish the range of applicability of our CF rDA process,
the syntheses of enantiomerically pure pyrrolo[1,2-a]pyrim-
idine 19 and pyrimido[2,1-a]isoindole 20 through rDA reaction
under CF conditions were undertaken (Scheme 4). The source
of chirality, (1R,2R,3S,4S)-3-amino-N-methylbicyclo[2.2.1]hept-5-
ene-2-carboxamide [(–)-1b] was prepared by known literature
protocols.[2e] In a stereocontrolled ring-closing reaction, (–)-1b
was treated with 3-oxo-3-(p-tolyl)propanoic acid to give (+)-4
as a single diastereoisomer in good yield. The ready loss of
cyclopentadiene through the CF rDA protocol at 220 °C resulted
in (S)-1-methyl-8a-(p-tolyl)-1,7,8,8a-tetrahydropyrrolo[1,2-a]pyr-
imidine-2,6-dione enantiomer (+)-19 in high yield (Table 1, en-
try 4) with an ee value of 97 %. When carboxamide (–)-1b was
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Table 1. CF process for the synthesis of pyrimidinones 17–25 under the opti-
mized reaction conditions.
Entry Starting Product CF Optimized reaction conditions
material Solvent[a] T Residence Yield[b]
[°C] time [min] [%]
1 2 17 MeCN 250 15 98
2 3 18 220 15 97
3 4 19 220 15 95
4 (+)-4 (+)-19 220 15 97
5 5 20 220 15 98
6 (+)-5 (–)-20 250 15 93
7 6 21 220 15 96
8 7 22 250 15 97
9 8 240 60 73
10 9 23 240 60 75
11 10 150 60 95
12 11 toluene/ 240 60 53
13 12 24 MeOH, 240 60 70
14 13 4:1 150 60 92
15 14 240 60 51
16 15 25 240 60 57
17 16 150 60 86
[a] Solvents were selected on the basis of solubilities. [b] Isolated yield.
treated with 2-formylbenzoic acid, pentacyclic isoindolo-
[1,2-a]quinazolinone (+)-5 was formed. CF-induced thermolysis
of (+)-5 at 250 °C gave the expected (S)-1-methyl-1,10b-di-
hydropyrimido[2,1-a]isoindole-2,6-dione [(–)-20] within a resi-
dence time of 15 min, with full conversion, in high yield, and
with an ee value of 98 % (Table 1, entry 6).
Our next CF rDA investigation was carried out with spiro-
quinazolinones 8–16, which have not been subjected to rDA
reactions previously through conventional batch approaches.
Spiroquinazolinone derivatives 8–16 were first subjected to CF
using the previously optimized parameters. They were dissolved
in MeCN and loaded into the CF reactor (Figure 1) at different
temperatures based on their melting points. An initial assess-
ment of the results revealed that compounds 8–16 underwent
thermal decomposition, but only moderate conversions were
observed with significant amounts of rDA degradation prod-
ucts. Following these disappointing results, we decided to opti-
Scheme 4. Solvent and conditions: (i) toluene, reflux, pTsA, 16 h; (ii) CF: toluene, pTsA, flow rate = 0.2 mL min–1; (iii) CF: MeCN, toluene, flow rate = 0.2 mL min–
1, 220 °C.
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mize our operating parameters further. We screened different
solvents, and found that a mixture of toluene and MeOH
(4:1 v/v) worked best to give new 2-spiropyrimidin-4-ones 23–
25. It is important to note that toluene is known to be an effec-
tive solvent under superheated CF rDA conditions.[9,33] This ef-
fect is even more pronounced when MeOH is used as a cosolv-
ent. The transformation of diexo-methylene-bridged 2-spiro-
quinazolinone 8 is illustrative. The substrate was dissolved in
toluene/MeOH (4:1), and the solution was introduced into the
heated 304 stainless steel coil reactor at 240 °C with a residence
time of 60 min (Table 1, entry 9). The residence time was in-
creased by using a longer coil in order to further improve the
conversion. Under these conditions, 1,5-diazaspiro[5.5]undec-3-
en-2-one (23) was isolated in a moderate yield of 73 %.
We also wanted to investigate the CF rDA reaction of diendo
isomer 9 in the hope that we could increase the yield of 23.
Since diendo stereoisomers are thermally unstable compared to
their diexo analogues, they undergo rDA reactions more easily.
Thus, 9 was subjected to the same conditions as described
above (Table 1, entry 10). With a residence time of 60 min, rDA
product 23 was obtained in almost the same yield (75 %) as
with diexo isomer 8. This result shows that a change in stereo-
chemistry does not have any significant effect on the reaction
yield. Subsequently, we turned to epoxy-bridged 2-spiroquinaz-
olinone 10 with the expectation that it would be much easier
to remove furan as the diene than cyclopentadiene, and that
this would be achieved at lower temperatures. This may im-
prove the yield by increasing the conversion and minimizing
the amount of degradation products because of the lower tem-
peratures used. Therefore, we used a temperature of 150 °C.
Complete conversion was obtained with a residence time of
60 min, and the desired spiro compound 23 was isolated in a
yield of 95 % (Table 1, entry 11). Encouraged by these promis-
ing results, a series of experiments was undertaken to gain a
better understanding of the effect of the thermally-driven CF
rDA on the transformation of other spiroquinazolinone scaf-
folds. Accordingly, we treated compounds 11–16 under the CF
reaction conditions described above. Benzylpiperidine deriva-
tive 24 and adamantane 25 were obtained in good yields of 92
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and 86 %, respectively (Table 1, entries 14 and 17). Importantly,
the yields obtained from the oxa-bridged spiro compunds were
always higher than those for the methylene-bridged analogues.
Based on our previous findings, we wanted to explore
whether spiro compounds 8–16 undergo thermal decomposi-
tion under conventional batch conditions. For this purpose, we
planned to test two different batch methods (Scheme 3). The
first method involved simple heating of compounds 8–16 at
their melting points; in the second method, the rDA reactions
were carried out under MW conditions. Thus, in solvent-free
experiments, compounds 8–16 were heated at around 10 °C
above their melting points. Although HPLC–MS analysis showed
full degradation of starting materials 8–16, rDA products 23–
25 were not detected in any case. In contrast, when MW irradia-
tion was used with spiroquinazolinone derivatives 8–16, we ob-
served slightly higher than medium or no conversion to the
retrodiene products 23–25.
The best MW-promoted cycloreversion for the synthesis of
compounds 23–25 was achieved when epoxy-spiroquinazolin-
ones 10, 13, and 16 were irradiated in 1,2-dichlorobenzene at
180 °C for 30 min. These conditions gave isolated yields of 78,
89, and 78 %, respectively (Figure 2). These yields are lower than
those obtained in the CF rDA process (Table 1, entries 11, 14,
and 17). A throughput comparison for spiropyrimidinones 23–
25 prepared by the batch and CF processes is shown in Fig-
ure 2. These data clearly demonstrate the superiority of CF tech-
nology compared to conventional batch methods.
Figure 2. Comparison in terms of isolated yields between the CF rDA and
MW processes for the synthesis of functionalized spiropyrimidinones 23–25.
MW-induced rDA (orange); CF rDA (blue).
Conclusions
A detailed investigation of the CF rDA reaction, a new and effi-
cient approach to the synthesis of pyrrolopyrimidinone (17–
19), pyrimidoisoindole (20–22), and spiropyrimidinone (23–25)
derivatives has been carried out. The preparation of intermedi-
ates 2–16 through domino ring closure or spirocyclization un-
der CF conditions was achieved in high yields; this protocol
represents an alternative time-efficient route. We proved that
the CF rDA process is able to yield more complex structures
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that are otherwise inaccessible. In the case of pyrrolo[1,2-a]-
quinazoline and isoindolo[2,1-a]quinazoline derivatives 2–7,
HPLC–MS measurements revealed full conversions to the de-
sired pyrrolopyrimidinones and isoindolopyrimidinones 17–22.
In contrast, only moderate conversions to new spiropyrimodi-
nones 23–25 were observed for the methylene-bridged spiro-
quinazolinones 8, 9, 11, 14, and 15. It is interesting that epoxy-
bridged spiroquinazolinones 10, 13, and 16, in which an oxy-
gen atom has been introduced at the 7-position of the
-aminonorbornene carboxamide skeleton, gave retrodiene
products 23–25 in almost quantitative yields. Importantly, the
stereochemistry (diendo vs. diexo condensation) of the starting
quinazolinones 8–16 was found to have no significant effect on
reaction yields. The CF reactor set-up ensured enhanced safety,
and gave yields higher than those obtained in batch and micro-
wave processes. This is particularly true for compounds 11, 14,
and 15, which were unreactive (0 % yield) under microwave
conditions; yields of 53, 51, and 57 %, respectively, were ob-
served under CF conditions. We envisage that this approach
could be readily extended to the preparation of other syntheti-
cally important building blocks that require harsh conditions in
batch methods.
Experimental Section
General Remarks: 1H NMR spectra were recorded at 400.13 MHz
or 500.20 MHz, and 13C NMR spectra were recorded at 100.62 MHz
or 125.77 MHz in CHCl3 or [D6]DMSO at ambient temperature, with
a Bruker AM 400 or a Bruker AscendTM 500 spectrometer. Chemical
shifts (δ) are given in parts per million (ppm) relative to tetramethyl-
silane (δ = 0 ppm), which was used as an internal standard. 1H NMR
spectra were calibrated using the residual solvent signals of CDCl3
(δ = 7.26 ppm) or [D6]DMSO (δ = 2.50 ppm). 13C NMR spectra were
calibrated using the signal of CDCl3 (δ = 77.16 ppm) or [D6]DMSO
(δ = 39.52 ppm). Signal multiplicities are reported as follows: s =
singlet, d = doublet, t = triplet, q = quartet, m = multiplet; ArH =
aromatic. Data for 13C NMR are reported in terms of chemical shift
(δ [ppm]) and multiplicity (C, CH, CH2, CH3 or NH). Coupling con-
stants (J) are reported to the nearest 0.1 Hz. Copies of the 1H and
13C spectra can be found in the Supporting Information. HPLC–MS
measurements were carried out with a Phenomenex 5 μm C18(2)
100 Å column (250 × 4.60 mm). The solvent systems used consisted
of AcOH (0.1 %) in water (A) and AcOH (0.1 %) in MeCN (B); gradient:
5–100 % B over 35 min, at a flow rate of 1 mL min–1. Chromato-
grams and spectra were recorded in positive-ion mode with electro-
spray ionization with a Thermo LCQ Fleet mass spectrometer. FTIR
spectra were obtained using KBr pastilles with an AVATAR 330 FTIR
Thermo Nicolet spectrometer. Flow reactions were carried out with
a modular flow system equipped with heated 304 stainless steel
tubing coils [Supelco premium grade 304 empty stainless steel tub-
ing; dimensions: length (L) × outer diameter (OD) × inner diameter
(ID) = 100 ft × 1/16 in × 0.03 in] and an adjustable back-pressure
regulator (ThalesNano, BPR, 0–300 bar). The tube reactor was
heated in a Heraeus oven to the desired temperatures. The pressure
was set at 10 bar, and the flow rate was kept at a constant value of
0.2 mL min–1. Microwave-promoted reactions were carried out in
sealed reaction vials (10 mL) in a microwave (CEM, Discover) cavity.
Melting points were measured with a Hinotex X4 micro melting-
point apparatus with a heating rate of 4 °C/min. Optical rotations
for the rDA products were recorded with a Perkin-Elmer 341
polarimeter. The corresponding ee values were 97 % for (+)-19 and
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98 % for (–)-20. Analysis of these compounds was carried out using
an HPLC instrument equipped with a Phenomenex IA column. For
(+)-19: n-hexane/iPrOH, 70:30, 0.1 % Et2NH, flow rate 0.5 mL min–1,
detection at 254 nm, tR = 63.50 min (antipode: 56.95 min); for (–)-
20: n-hexane/iPrOH , 70:30, flow rate 1.0 mL min–1, detection at
254 nm, tR = 28.50 min (antipode: 22.51 min). All physical and spec-
troscopic data of fused pyrimidinones 2–22 were identical with the
corresponding literature data.[2l,2m,2o,2q,2r]
General Procedures for Flow Reactions
Synthesis of Ring-Closure Products 2–16
Synthesis of Pyrrolo[1,2-a]quinazolines 2, 3, 4 and Isoindolo-
[1,2-a]quinazolines 5, 6, and 7: A mixture of diexo-3-aminobicy-
clo[2.2.1]hept-5-ene-2-carboxamide (1a) or diexo-3-amino-N-meth-
ylbicyclo[2.2.1]hept-5-ene-2-carboxamide (1b) (1 mmol) and either
levulinic acid, 3-oxo-3-(p-tolyl)propanoic acid, 2-formylbenzoic acid,
2-acetylbenzoic acid, or 2-(4-methylbenzoyl)benzoic acid (1.2 mmol)
along with a catalytic amount of pTsA was dissolved in toluene
(50 mL). The system temperature was set to 110 °C, the pressure to
10 bar, and the flow rate to 0.2 mL min–1. When the pressure and
the temperature of the flow system were stable, the solution loaded
into the reactor was passed through the heated reactor coil with a
reaction time of 6 h. The flow output was collected. The solvent
was removed by evaporation, and the solid residue was dissolved
in EtOAc/MeOH, 9:1 (v/v). The solution was transferred to a neutral
SiO2 column, which was eluted with the same solvent mixture. The
analytical and spectroscopic data of 2–7 were identical to those
found in the literature.[2l,2m]
(3aR*,5aR*,6R*,9S*,9aS*)-3a-Methyl-2,3,3a,4,5a,6,9,9a-octa-
hydro-6,9-methanopyrrolo[1,2-a]quinazoline-1,5-dione (2): Col-
ourless crystals (93 %). M.p. 239–242 °C. HPLC–MS (ESI): tR =
12.00 min, m/z = 233 [M + H]+, 167 [MrDA + H]+. The analytical
and spectroscopic data of 2 were identical to those reported in the
literature.[2l]
(3aR*,5aR*,6R*,9S*,9aS*)-6,9-Methano-3a,4-dimethyl-
2,3,3a,4,5a,6,9,9aoctahydropyrrolo[1,2-a]quinazoline-1,5-dione
(3): Colourless crystals (85 %). M.p. 207–209 °C. HPLC–MS (ESI): tR =
13.89 min, m/z = 247 [M + H]+, 181 [MrDA + H]+. The analytical
and spectroscopic data of 3 were identical to those reported in the
literature.[2m]
(3aS*,5aR*,6R*,9S*,9aS*)-6,9-Methano-4-Methyl-3a-(p-tolyl)-
2,3,3a,4,5a,6,9,9a-octahydropyrrolo[1,2-a]quinazoline-1,5-di-
one (4): Colourless crystals (79 %). M.p. 214–216 °C. HPLC–MS (ESI):
tR = 24.49 min, m/z = 323 [M + H]+, 229 [MrDA + H]+. The analytical
and spectroscopic data of 4 were identical to those reported in the
literature.[2m]
( 1S * , 4R * , 4aR * , 6aS * , 12aS * ) -1 ,4 -Methano -6 -methy l -
1,4,4a,6,6a,12a-hexahydroisoindolo[2,1-a]quinazoline-5,11-di-
one (5): Colourless crystals (90 %). M.p. 197–198 °C. HPLC–MS (ESI):
tR = 18.70 min, m/z = 281 [M + H]+, 215 [MrDA + H]+. The analytical
and spectroscopic data of 5 were identical to those reported in the
literature.[2m]
(1S*,4R*,4aR*,6aR*,12aS*)-1,4-Methano-6,6a-dimethyl-
1,4,4a,6,6a,12a-hexahydroisoindolo[2,1-a]quinazoline-5,11-di-
one (6): Colourless crystals (83 %). M.p. 196–197 °C. HPLC–MS (ESI):
tR = 21.84 min, m/z = 295 [M + H]+, 229 [MrDA + H]+. The analytical
and spectroscopic data of 6 were identical to those reported in the
literature.[2m]
(1S*,4R*,4aR*,6aR*,12aS*)-1,4-Methano-6-methyl-6a-(p-tolyl)-
1,4,4a,6,6a,12a-hexahydroisoindolo[2,1-a]quinazoline-5,11-di-
one (7): Colourless crystals (85 %). M.p. 230–232 °C. HPLC–MS (ESI):
Eur. J. Org. Chem. 2018, 4456–4464 www.eurjoc.org © 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim4461
tR = 31.72 min, m/z = 371 [M + H]+, 305 [MrDA + H]+. The analytical
and spectroscopic data of 7 were identical to those reported in the
literature.[2m]
Synthesis of Enantiomeric Pyrrolo[1,2-a]quinazoline (+)-4 and
Isoindolo[1,2-a]quinazoline (+)-5: A mixture of (–)-(1R,2R,3S,4S)-3-
amino-N-methylbicyclo[2.2.1]hept-5-ene-2-carboxamide [(–)-1b,
1 mmol] and either 3-oxo-3-(p-tolyl)propanoic acid or 2-formylben-
zoic acid (1.2 mmol) along with pTsA (5 mg) in toluene (50 mL) was
introduced into the flow reactor at a temperature of 110 °C, using
the same flow rate (0.2 mL min–1). The product mixture (brownish-
yellow colour) leaving the flow system was evaporated. The residue
was dissolved in EtOAc/MeOH (9:1) eluent, and this material was
directly transferred onto a short SiO2 column. The 1H and 13C NMR
spectroscopic data for the optically active compounds were consist-
ent with those reported for the racemates.
(+)-(3aR,5aR,6R,9S,9aS)-6,9-Methano-4-methyl-3a-(p-tolyl)-
2,3,3a,4,5a,6,9,9a-octahydropyrrolo[1,2-a]quinazoline-1,5-di-
one [(+)-4]: Colourless crystals (82 %). M.p. 206–208 °C. [α]D25 =
+10.8 (c = 0.33, MeOH).
( + ) - ( 1S , 4R , 4 aR , 6 aS , 1 2aS ) - 1 , 4 –Me thano - 6 -me thy l -
1,4,4a,6,6a,12a-hexahydroisoindolo[2,1-a]quinazoline-5,11-di-
one [(+)-5]: Colourless crystals (83 %). M.p. 250–252 °C. [α]D25 = +62
(c = 0.48, MeOH).
Preparation of Spiroquinazolinones 8–16: A solution of amino-
carboxamide 1a, 1c, or 1d (1 mmol) and either cyclohexanone, 1-
benzylpiperidine, or adamantanone (1.2 mmol) in EtOH (50 mL),
was fed into the reactor, and passed through the heated reactor
coil at 100 °C with a reaction time of 6 h. The flow output was
collected. The solvent was removed by evaporation, and the re-
maining residue was dissolved in Et2O (5 mL). The resulting crystals
were collected by filtration and washed with Et2O. The analytical
and spectroscopic data on 8–16 were identical to those reported
in the literature.[2o–2r]
(4aR*,5R*,8S*,8aS*)-4a,5,8,8a-Tetrahydro-1H-spiro[5,8-meth-
anoquinazoline-2,1′-cyclohexan]-4(3H)-one (8): Colourless pow-
der (95 %). M.p. 232–235 °C. HPLC–MS (ESI): tR = 6.52 min, m/z =
233 [M + H]+, 167 [MrDA + H]+. The analytical and spectroscopic
data of 8 were identical to those reported in the literature.[2q]
(4aS*,5R*,8S*,8aR*)-4a,5,8,8a-Tetrahydro-1H-spiro[5,8-meth-
anoquinazoline-2,1′-cyclohexan]-4(3H)-one (9): Colourless pow-
der (98 %). M.p. 243–244 °C. HPLC–MS (ESI): tR = 6.23 min, m/z =
233 [M + H]+, 167 [MrDA + H]+. The analytical and spectroscopic
data of 9 were identical to those reported in the literature.[2o]
(4aS*,5R*,8S*,8aR*)-4a,5,8,8a-Tetrahydro-1H-spiro[5,8-epoxy-
quinazoline-2,1′-cyclohexan]-4(3H)-one (10): Colourless crystals
(89 %). M.p. 158–160 °C. HPLC–MS (ESI): tR = 6.49 min, m/z = 235
[M + H]+, 167 [MrDA + H]+. The analytical and spectroscopic data of
10 were identical to those reported in the literature.[2o]
(4aR*,5R*,8S*,8aS*)-1 ′-Benzyl-4a,5,8,8a-tetrahydro-1H-
spiro[5,8-methanoquinazoline-2,4′-piperidin]-4(3H)-one (11):
Colourless powder (95 %). M.p. 217–220 °C. HPLC–MS (ESI): tR =
9.7 min, m/z = 324 [M + H]+, 258 [MrDA + H]+. The analytical and
spectroscopic data of 11 were identical to those reported in the
literature.[2q]
(4aS*,5R*,8S*,8aR*)-1 ′-Benzyl-4a,5,8,8a-tetrahydro-1H-
spiro[5,8-methanoquinazoline-2,4′-piperidin]-4(3H)-one (12):
White powder (92 %). M.p. 248–250 °C. 1H NMR (500 MHz,
[D6]DMSO): δ = 0.63 (d, J = 10.96 Hz, 1 H, 9-H), 1.35–1.41 (m, 3 H,
9-H, CH2), 1.47–1.69 (m, 2 H, CH2), 1.87 (m, J = 12.8 Hz, 1 H, 1-NH),
2.24–2.4 (m, 4 H, CH2), 2.96 (s, 1 H, 8-H), 3.14 (s, 1 H, 5-H), 3.44 (s, 2
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H, NCH2Ar), 3.72 (t, J = 8.6 Hz, 1 H, 8a-H), 6.14–6.21 (m, 2 H, 6-H, 7-
H), 7.20–7.32 (m, 5 H, ArH), 7.79 (s, 1 H, 3-NH) ppm. 13C NMR
(125.77 MHz, CDCl3): δ = 36.53, 37.50, 42.80, 45.86, 46.37, 47.02,
49.03, 49.72, 54.39, 62.40, 67.87, 127.27, 127.29, 128.59. 128.61,
129.21, 129.24, 133.87, 133.89, 139.34, 139.36, 171.47. HPLC–MS
(ESI): tR = 9.42 min, m/z = 324 [M + H]+, 258 [MrDA + H]+.
(4aS*,5R*,8S*,8aR*)-1 ′-Benzyl-4a,5,8,8a-tetrahydro-1H-
spiro[5,8-epoxyquinazoline-2,4′-piperidin]-4(3H)-one (13): Col-
ourless powder (90 %). M.p. 196–197 °C. 1H NMR (500 MHz, CDCl3):
δ = 1.6–1.9 (m, 4 H, CH2), 1.85–1.95 (m, 1 H, 1-NH), 2.14 (d, J =
6.5 Hz, 1 H, 4a-H), 2.48–2.64 (m, 4 H, CH2), 3.36 (s, 1 H, 8a-H), 3.54
(s, 2 H, NCH2Ar), 4.84 (s, 1 H, 8-H), 5.42 (s, 1 H, 5-H), 6.31 (s, 1 H, 3-
NH), 6.36 (dd, J = 5.8, J = 1.5 Hz, 1 H, 7-H), 6.57 (dd, J = 5.86, J =
1.45 Hz, 1 H, 6-H) , 7 .27–7.33 (m, 1 H, ArH) ppm. 13C NMR
(125.77 MHz, CDCl3): δ = 35.8, 42.8, 48.8, 49.4, 52.4, 62.7, 67.9, 81.8,
83.2, 128.3, 129.0, 133.5, 138.5, 170.3. HPLC–MS (ESI): tR = 6.86 min,
m/z = 326 [M + H]+, 258 [MrDA + H]+.
(4aR*,5R*,8S*,8aS*)-4a,5,8,8a-Tetrahydro-1H-spiro[5,8-meth-
anoquinazoline-2,2′-adamantan]-4(3H)-one (14): Colourless
powder (82 %). M.p. 218–220 °C. HPLC–MS (ESI): tR = 12.45 min,
m/z = 285 [M + H]+, 219 [MrDA + H]+. The analytical and spectro-
scopic data of 14 were identical to those reported in the litera-
ture.[2r]
(4aS*,5R*,8S*,8aR*)-4a,5,8,8a-Tetrahydro-1H-spiro[5,8-meth-
anoquinazoline-2,2′-adamantan]-4(3H)-one (15): Colourless crys-
tals (83 %). M.p. 207–210 °C. HPLC–MS (ESI): tR = 11.49 min, m/z =
285 [M + H]+, 219 [MrDA + H]+. The analytical and spectroscopic
data of 15 were identical to those reported in the literature.[2r]
(4aS*,5R*,8S*,8aR*)-4a,5,8,8a-Tetrahydro-1H-spiro[5,8-epoxy-
quinazoline-2,2′-adamantan]-4(3H)-one (16): Colourless crystals
(79 %). M.p. 175–178 °C. HPLC–MS (ESI): tR = 14.19 min, m/z = 287
[M + H]+, 219 [MrDA + H]+. The analytical and spectroscopic data of
16 were identical to those reported in the literature.[2r]
Synthesis of Retrodiene Products 17–22
Preparation of Racemic Pyrrolo[1,2-a]pyrimidines 17–19 and
Pyrimido[1,2-a]isoindoles 20–22: Compounds 2–7 (100 mg) were
each introduced into the flow reactor in a solution of MeCN (25 mL).
The solution was inserted into the reactor, and passed through the
heated reactor coil at 220 °C or 250 °C (for 2 and 7), with a residence
time of 15 min, and the flow output was collected. The solvent was
removed by evaporation, and the residue was dissolved in Et2O
(5 mL). The resulting crystals were collected by filtration and
washed with Et2O.
8a-Methyl-1,7,8,8a-tetrahydropyrrolo[1,2-a]pyrimidine-2,6-di-
one (17): Colourless crystals (98 %). M.p. 165–166 °C. 1H NMR
(500 MHz, [D6]DMSO): δ = 1.41 (s, 3 H, CH3), 2.03–2.18 (m, 2 H, CH2),
2.41–2.47 (m, 1 H, CH2), 2.67–2.58 (m, 1 H, CH2), 5.24 (dd, J = 7.70,
J = 1.90 Hz, 1-H, 3-H), 7.30–7.32 (d, J = 7.72 Hz, 1 H, 4-H), 8.22 (s, 1
H, NH) ppm. 13C NMR (125.77 MHz, [D6]DMSO): δ = 24.5, 29.5, 33.9,
73.6, 105.5, 131.2, 163.58, 170.8 ppm. HPLC–MS (ESI): tR = 7.11 min,
m/z = 167 [M + H]+.
1,8a-Dimethyl-8,8a-dihydropyrrolo[1,2-a]pyrimidine -
2,6(1H,7H)-dione (18): Colourless crystals (98 %). M.p. 130–131 °C.
1H NMR (500 MHz, CDCl3): δ = 1.46 (s, 3 H, 8a-CH3), 2.25–2.36 (m, 2
H, CH2), 2.52–2.66 (m, 2 H, CH2), 2.9 (s, 3 H, 1-CH3), 5.47 (d, J =
7.6 Hz, 1 H, 3-H), 7.27 (d, J = 6.49 Hz, 1 H, 4-H) ppm. 13C NMR
(125.77 MHz, CDCl3): δ = 19.4, 26.9, 29.6, 32.8, 106.0 129.6, 163.3,
169.7 ppm. HPLC–MS (ESI): tR = 9.12 min, m/z = 181 [M + H]+.
1-Methyl-8a-(p-tolyl)-8,8a-dihydropyrrolo[1,2-a]pyrimidine-
2,6(1H,7H)-dione (19): Colourless crystals (99 %). M.p. 121–123 °C.
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1H NMR (500 MHz, CDCl3): δ = 2.34 (s, 3 H, ArCH3), 2.61–2.74 (m, 4
H, CH2), 3.16 (s, 3 H, 1-CH3), 5.48 (d, J = 7.66 Hz, 1 H, 3-H), 7.08 (d,
J = 8.35 Hz, 2 H, , Ar), 7.17 (d, J = 8.04 Hz, 2 H, Ar), 7.32 (d, J =
7.64 Hz, 1 H, , 4-H) ppm. 13C NMR (125.77 MHz, CDCl3): δ = 20.9,
29.6, 30.0, 33.7, 80.3, 107.6, 124.7, 129.6, 130.3, 137.1, 139.2, 163.6,
170.8 ppm. HPLC–MS (ESI): tR = 19.56 min, m/z = 257 [M + H]+.
1-Methyl-1,10b-dihydropyrimido[2,1-a]isoindole-2,6-dione
(20): Colourless crystals (98 %). M.p. 165–167 °C. 1H NMR (500 MHz,
CDCl3): δ = 3.20 (s, 3 H, CH3), 5.64 (d, J = 7.51 Hz, 1 H, 4-H), 5.99 (s,
1 H, 10b-H), 7.63–7.76 (m, 4 H, Ar), 7.98 (d, J = 7.51 Hz, 1 H, 3-H)
ppm. 13C NMR (125.77 MHz, CDCl3): δ = 29.2, 70.9, 107.2, 125.3,
125.4, 130.6, 131.9, 132.7, 133.1, 138.7, 164.2, 165.4 ppm. HPLC–MS
(ESI): tR = 15.44 min, m/z = 215 [M + H]+.
1,10b-Dimethyl-1,10b-dihydropyrimido[2,1-a]isoindole-2,6-di-
one (21): Colourless crystals (98 %). M.p. 236–238 °C. 1H NMR
(500 MHz, CDCl3): δ = 1.72 (s, 3 H, 10b-CH3), 3.13 (s, 3 H, 1-CH3),
5.72 (d, J = 7.48 Hz, 1 H, 4-H), 7.54 (d, J = 7.49 Hz, 1 H, Ar), 7.63–
7.76 (m, 3 H, Ar), 7.97 (d, J = 8.04 Hz, 1 H, 3-H) ppm. 13C NMR
(125.77 MHz, CDCl3): δ = 22.4, 28.4, 107.8, 124.5, 125.3, 130.3, 130.3,
130.8, 133.2, 144.4, 163.9, 164.4 ppm. HPLC–MS (ESI): tR = 16.80 min,
m/z = 229 [M + H]+.
1-Methyl-10b-(p-tolyl)-1,10b-dihydropyrimido[2,1-a]isoindole-
2,6-dione (22): Colourless crystals (95 %). M.p. 183–184 °C. 1H NMR
(500 MHz, CDCl3): δ = 2.31 (s, 3 H, ArCH3), 3.31 (s, 3 H, 1-CH3), 5.64
(d, J = 7.44 Hz, 1-H, 4-H), 6.85 (d, J = 8.34 Hz, 2 H, ArH), 7.09 (d, J =
7.93 Hz, 1 H, ArH), 7.36 (d, J = 7.42 Hz, 2 H, ArH), 7.62–7.66 (m, 2 H,
ArH), 8.03–8.04 (m, 1 H, 3-H) ppm. 13C NMR (125.77 MHz, CDCl3):
δ = 21.0, 30.8, 81.1, 108.8, 125.0 126.0, 126.1, 129.5, 130.4, 130.6,
130.7, 133.5, 134.8, 139.2, 145.1, 165.1, 165.3 ppm. HPLC–MS (ESI):
tR = 25.70 min, m/z = 305 [M + H]+.
Preparation of Enantiomeric Pyrrolo[1,2-a]pyrimidine (+)-19
and Pyrimido[1,2-a]isoindole (–)-20: A solution of pyrrolo-
[1,2-a]quinazoline derivative (–)-4 (100 mg) or isoindolo[2,1-a]quin-
azoline derivative (+)-5 (100 mg) in MeCN (25 mL) was introduced
into the flow reactor at a temperature of 220 °C, using the same
flow rate (0.2 mL min–1), with a residence time of 15 min. The flow
output was collected, and the solvent was removed by evaporation.
The residue was dissolved in Et2O (1 mL). The resulting crystals were
collected by filtration and washed with Et2O. The 1H and 13C NMR
spectroscopic data for the optically active compounds were consist-
ent with those reported for the racemates.
(+)-(S)-1-Methyl-8a-(p-tolyl)-8,8a-dihydropyrrolo[1,2-a]pyr-
imidine-2,6(1H,7H)-dione [(+)-19]: Colourless crystals (97 %). M.p.
167–169 °C. [α]D25 = +195 (c = 0.3, MeOH); 97 % ee.
(–)-(S)-1-Methyl-1,10b-dihydropyrimido[2,1-a]isoindole-2,6-di-
one [(–)-20]: Colourless crystals (98 %). M.p. 203–205 °C [α]D25 =
–310 (c = 0.3, MeOH); 98 % ee.
Synthesis of Spiropyrimidinones 23–25: Spiroquinazoline deriva-
tives 8–16 (100 mg) were each introduced into the flow reactor in
solution in toluene/MeOH (4:1; 25 mL). The solution was inserted
into the reactor and passed through the heated reactor coil, at
150 °C for the epoxy-bridged 10, 13, and 16, or 240 °C for the
methylene-bridged 8, 9, 11, 12, 14, and 15, with a residence time
of 60 min. The flow output was collected, and the solvent was re-
moved by evaporation. The residue was dissolved in EtOAc/MeOH
(9:1); this material was transferred to a SiO2 column, which was
eluted with EtOAc/MeOH (9:1.
1,5-Diazaspiro[5.5]undec-3-en-2-one (23): Brownish crystals
(95 %). M.p. 160–164 °C. IR (KBr): ν˜ = 3263, 3025, 2939, 2863, 1627,
1516, 1434, 1337, 1213, 1122, 793, 730, 654 cm–1. 1H NMR (500 MHz,
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[D6]DMSO): δ = 1.18–1.79 (m, 10 H, CH2), 4.31 (d, J = 7.2 Hz, 1 H, 3-
H), 6.74–6.77 (m, 2 H, 4-H, NH), 6.96 (s, 1 H, NH) ppm. 13C NMR
(125.77 MHz, CDCl3): δ = 21.7, 24.6, 36.9, 68.8, 92.2, 142.6, 166.2
ppm. HPLC–MS (ESI): tR = 10.72 min, m/z = 167 [M + H]+.
9-Benzyl-1,5,9-triazaspiro[5.5]undec-3-en-2-one (24): White
crystals (92 %). M.p. 192–195 °C. IR (KBr): ν˜ = 3243, 3026, 2947, 2808,
1614, 1527, 1424, 1219, 1104, 792, 739 cm–1. 1H NMR (500 MHz,
[D6]DMSO): δ = 1.96 (m, 4 H, CH2), 2.48 (m, 4 H, CH2), 3.53 (s, 2 H,
NCH2Ar), 4.49 (s, 1 H, NH), 4.80 (d, J = 7.39 Hz, 3-H, CH), 5.39 (s, 1
H, NH), 6.77–6.80 (t, J = 6.64 Hz, 1 H, 4-H), 7.28–7.34 (m, 5 H, ArH)
ppm. 13C NMR (125.77 MHz, [D6]DMSO): δ = 34.0, 36.6, 48.9, 49.4,
62.7, 67.3, 92.7, 127.3, 128.4, 129.1, 142.7, 166.0 ppm. HPLC–MS
(ESI): tR = 257.15 min, m/z = 258 [M + H]+.
1′H-Spiro[adamantane-2,2′-pyrimidin]-4′(3′H)-one (25): Brown-
ish crystals (86 %). M.p. 220–212 °C. IR (KBr): ν˜ = 3308, 2910, 1633,
1391, 1244, 1101, 783, 668, 618 cm–1. 1H NMR (500 MHz, CDCl3):
δ = 1.74–1.95 (m, 16 H, adamantane), 2.28 (m, 2 H, adamantane),
4.79 (m, 1 H, 5-H), 5.76 (m), 6.74–6.77 (m, 2 H, 4-H, NH), 6.85 (s, 1
H, 6-H) ppm. 13C NMR (125.77 MHz, CDCl3): δ = 26.1, 26.4, 32.3,
33.2. 35.0, 37.5, 71.9, 92.1, 142.8, 166.2 ppm. HPLC–MS (ESI): tR =
18.10 min, m/z = 219 [M + H]+.
General Procedure for Batch Reactions
Compounds 2–13 were prepared by the previously reported meth-
ods.[2l–2q]
Preparation of Spiroquinazolinone Derivatives 14–16: -aminor-
bornene carboxamide 1a, 1c, or 1d (1 mmol) was placed in a micro-
wave test tube (10 mL) containing a magnetic stirrer bar and EtOH
(2 mL). The reaction vial was then sealed with a Teflon cap, and
placed into the CEM Discover microwave reactor. The solution was
irradiated (150 W) for a period of 1 h at 100 °C. The resulting solu-
tion was transferred onto a SiO2 column, which was eluted with
toluene/MeOH (4:1).
(4aR*,5R*,8S*,8aS*)-4a,5,8,8a-Tetrahydro-1H-spiro[5,8-meth-
anoquinazoline-2,2′-adamantan]-4(3H)-one (14): Colourless
powder (75 %). M.p. 215–220 °C.
(4aS*,5R*,8S*,8aR*)-4a,5,8,8a-Tetrahydro-1H-spiro[5,8-meth-
anoquinazoline-2,2′-adamantan]-4(3H)-one (15): Colourless crys-
tals (77 %). M.p. 210–211 °C.
(4aS*,5R*,8S*,8aR*)-4a,5,8,8a-Tetrahydro-1H-spiro[5,8-epoxy-
quinazoline-2,2′-adamantan]-4(3H)-one (16): Colourless crystals
(76 %). M.p. 175–181 °C.
Microwave-Induced rDA Reactions of 8–16: Microwave-mediated
reactions were carried out in sealed reaction vials. Heterocycle 8–16
(200 mg) was placed in a microwave test tube (10 mL) containing
a magnetic stirrer bar and 1,2-DCB (2 mL). The reaction vial was
then sealed with a Teflon cap, and placed into the CEM Discover
microwave reactor. The solution was irradiated (250 W) for a period
of 30 min at 200 °C for 8, 9, 11, 12, 15, and 16, and at 180 °C
for 10, 13, and 16. The solution was cooled, and the solvent was
evaporated. The residue was dissolved in n-hexane/EtOAc (1:1) elu-
ent, and the resulting solution was transferred to a SiO2 column.
The yields of the products 23–25 are given in Figure 2. For 11, 14,
and 15, decomposition took place, and the formation of rDA prod-
ucts was not observed.
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